Medigene (MDG1) Stock Price, News & Analysis

Company Overview

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Key Stats

• Today's Range: €0.13 to €0.13
• 50-Day Range: €0.13 to €0.13
• 52-Week Range: €1.60 to €5.51
• Volume: N/A
• Average Volume: 306,207 shs
• Market Capitalization: €1.02 million
• P/E Ratio: N/A
• Dividend Yield: 1.31%
• Price Target: N/A
• Consensus Rating: N/A

MDG1 Stock Analysis - Frequently Asked Questions

How have MDG1 shares performed this year?

Medigene's stock was trading at €1.03 at the beginning of 2025. Since then, MDG1 shares have decreased by 87.0% and is now trading at €0.13.

What other stocks do shareholders of Medigene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ETR:MDG1
• CIK: N/A
• Web: www.medigene.de
• Phone: +49-89-2000330
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): (€0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 7.12
• Net Income: -€4.67 million
• Net Margins: -249.83%
• Pretax Margin: N/A
• Return on Equity: -80.38%
• Return on Assets: -27.15%

Debt

• Debt-to-Equity Ratio: 12.95
• Current Ratio: 2.39
• Quick Ratio: 5.85

Sales & Book Value

• Annual Sales: €1.87 million
• Price / Sales: 0.54
• Cash Flow: €0.10 per share
• Price / Cash Flow: 1.37
• Book Value: €0.72 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 7,619,243
• Free Float: N/A
• Market Cap: €1.02 million
• Optionable: Not Optionable
• Beta: 0.84